Three strategies for managing loss of exclusivity successfully
pharmaphorum
FEBRUARY 18, 2021
Eli Lilly’s Humalog compound and formulation patents expired in 2013 and 2014, respectively. In late 2017, the FDA approved Admelog, Sanofi’s biosimilar of Humalog. Since losing exclusive rights in 2017, Pfizer undertook an over-the-counter switching strategy to guard against revenue loss.
Let's personalize your content